Indian Pharma Sector Gains as U.S. Waives Tariffs on Drug Imports

India ’s pharmaceutical sector has emerged as a key beneficiary of the U.S. decision to exempt drug imports from reciprocal tariffs affecting around 60 countries. While a 27% tariff applies to other goods, pharmaceuticals have been spared, recognizing India ’s critical role in global generic medicine production. Industry experts state that this move reinforces India’s position as a global pharma powerhouse. The exemption highlights the significance of affordable, life-saving generics to public health, economic stability, and national security. India exports $8.7 billion worth of pharmaceuticals to the U.S.

annually, while importing only $800 million. The U.S. healthcare system relies heavily on Indian generics and Chinese active pharmaceutical ingredients (APIs). Interruptions in these supply chains could significantly affect patient care in the U.S. The tariff exemption also creates an…